Cognetivity Neurosciences Ltd.
CGNSF · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2020 | |
|---|---|---|---|---|
| Revenue | $45 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2,175 | $25 | $11 | $9 |
| Gross Profit | -$2,130 | -$25 | -$11 | -$9 |
| % Margin | -4,694.9% | – | – | – |
| R&D Expenses | $601 | $491 | $71 | $492 |
| G&A Expenses | $5,039 | $11,522 | $2,087 | $1,608 |
| SG&A Expenses | $5,615 | $12,468 | $2,317 | $2,010 |
| Sales & Mktg Exp. | $576 | $946 | $231 | $402 |
| Other Operating Expenses | -$2,055 | -$3,999 | -$1,111 | $103 |
| Operating Expenses | $4,161 | $8,960 | $1,278 | $2,606 |
| Operating Income | -$6,291 | -$13,036 | -$2,393 | -$2,605 |
| % Margin | -13,866.4% | – | – | – |
| Other Income/Exp. Net | -$1,143 | -$148 | $467 | $0 |
| Pre-Tax Income | -$7,434 | -$13,127 | -$1,926 | -$2,660 |
| Tax Expense | $0 | $0 | $2 | -$15 |
| Net Income | -$7,434 | -$13,127 | -$1,928 | -$2,645 |
| % Margin | -16,386.3% | – | – | – |
| EPS | -0.087 | -0.18 | -0.033 | -0.058 |
| % Growth | 51.4% | -447.1% | 43.3% | – |
| EPS Diluted | -0.087 | -0.18 | -0.033 | -0.058 |
| Weighted Avg Shares Out | 85,049 | 73,057 | 58,675 | 45,598 |
| Weighted Avg Shares Out Dil | 85,049 | 73,057 | 58,675 | 45,598 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,027 | $61 | $63 | $56 |
| Depreciation & Amortization | $25 | $25 | $11 | $9 |
| EBITDA | -$6,382 | -$13,012 | -$2,393 | -$2,596 |
| % Margin | -14,067.1% | – | – | – |